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ABSTRACT
Background: Sarcopenia refers to the reduction of both volume and number of 
skeletal muscle fibers. Lean body mass loss is associated with survival, quality of life 
and tolerance to treatment in cancer patients. The aim of our study is to analyse the 
association between toxicities and sarcopenia in early breast cancer patients receiving 
adjuvant treatment. 
Materials and Methods: Breast cancer patients who have received anthracycline-
based adjuvant treatment were retrospectively enrolled. CT scan images performed 
before, during and after adjuvant chemotherapy were used to evaluate lean body 
mass at third lumbar vertebra level with the software Slice Omatic V 5.0.
Results: 21 stage I–III breast cancer patients were enrolled. According to the 
skeletal muscle index at third lumbar vertebra cut-off ≤38.5 cm2/m2, 8 patients 
(38.1%) were classified as sarcopenic before starting treatment, while 10 patients 
(47.6%) were sarcopenic at the end of treatment. A lower baseline L3 skeletal muscle 
index is associated with G3-4 vs G0-2 toxicities (33.4 cm2/m2 (31.1–39.9) vs 40.5 
cm2/m2 (33.4–52.0), p = 0.028). Similarly skeletal muscle cross sectional area was 
significantly lower in patients with G3-4 toxicities (86.7 cm2 (82.6–104.7) vs 109.0 
cm2 (83.3–143.9), p = 0.017). L3 skeletal muscle index is an independent predictor 
of severe toxicity (p = 0.0282) in multivariate analysis.
Conclusion: Lean body mass loss is associated with higher grade of toxicity in 
early breast cancer patients receiving adjuvant chemotherapy.
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INTRODUCTION
Sarcopenia, historically referred to the age-related 
reduction of both volume and number of muscle fibers. It 
leads to a functional capacity impairment with decreased 
strength, metabolic rate and aerobic capacity [1, 2].
Sarcopenia shows a multifactorial origin including 
disuse, endocrine function alterations, chronic diseases, 
inflammation and nutritional deficiencies [3]. Contrary 
to cachexia, sarcopenia may occur without a concomitant 
loss of fat mass and with a various percentage of lean body 
mass reduction. 
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Lean body mass (LBM) is the predominant source 
of organism proteins which are essentials for any cellular 
process. Moreover, a loss of LBM and an excessive protein 
catabolism, as it happens in cancer patients, may lead to a 
decline in immune activity with increased adverse clinical 
outcomes [4]. Protein synthesis dysregulation may be 
responsible for sarcopenia. Indeed, an inadequate response 
to anabolic stimuli or the upregulation of proteolysis in 
cancer are the principle causes of muscles loss [4]. In 
several studies, it has been showed that a lower LBM 
is associated with decreased survival, quality of life 
and tolerance to treatment [5]. The study of both fat 
and LBM at the level of the third lumbar vertebra (L3), 
performed by dual-energy X-ray absorptiometry (DXA) 
and/or computed tomography (CT) scan, appears to be 
strongly predictive of the entire body composition [6–10]. 
Indeed, CT scan provide details on each inspected muscle, 
adipose tissue and organs, representing an objective and 
reproducible technique for sarcopenia evaluation as well 
as cancer stage assessment [7].
The exact prevalence of sarcopenia is currently 
unknown, due to the variety of definitions proposed, 
the various techniques used to detect it and the different 
frequencies described in several diseases [11–13]. 
However, a careful estimation of sarcopenia and changes 
in body composition could represent an important way to 
prevent chemotherapy toxicity and to improve quality of 
life and survival of cancer patients. 
In this retrospective analysis, we studied the 
association between sarcopenia and toxicity in early breast 
cancer patients receiving adjuvant treatment.
RESULTS
Twenty-one stage I–III breast cancer patients who 
have received anthracycline-based adjuvant treatment 
at the Department of Medical Oncology, Sant’Andrea 
Hospital of Rome between February 2013 and April 
2014 were retrospectively enrolled. The median age 
was 54 years (range: 39–72 years). Tumor histology, 
HER-2 and hormonal status as well as more detailed 
information about surgery and chemotherapy are shown 
in Table 1. The median body composition parameters, 
i.e Body Mass Index (BMI), Body Surface Area (BSA), 
L3 Skeletal Muscle Index (L3 SMI) and Skeletal 
Muscle Cross Sectional Area (CSA) at baseline and 
after 4 cycles of chemotherapy are reported in Table 
2. Using the cut off ≤ 38.5 cm2/m2 for L3 SMI to 
define sarcopenia, 8 patients (38.1%) were sarcopenic 
before starting treatment and 10 patients (47.6%) after 
4 cycles of chemotherapy, with a 9.5% increase in 
frequency during treatment [11]. Only 2 patients (9.5%) 
were obese (BMI 31.2 and 33.7 respectively), but not 
sarcopenic. A proportion of 33.3% of the patients were 
overweight, 14.2% of witch sarcopenic according to 
≤38.5 cm2/m2 cut-off.
Overall, we observed G3-4 toxicity in 19% of the 
cases, mainly neutropenia (9.5%), vomit (4.8%), diarrhea 
(4.8%), mucositis (4.8%) and abdominal pain (4.8%), as 
showed in Table 3. 
The baseline value of L3 SMI has been shown to 
be significantly lower in patients with G3-4 toxicities 
compared to patients with G0-2 toxicities (33.4 cm2/m2 
(31.1–39.9) vs 40.5 cm2/m2 (33.4–52.0) respectively, 
p = 0.028). Moreover, also the skeletal muscle CSA was 
significantly lower in G3-4 compared to patients with 
G0-2 toxicities (86.7 cm2 (82.6–104.7) vs 109.0 cm2 (83.3–
143.9) respectively, p = 0.017). Meanwhile, BSA and 
BMI values were not associated with toxicities (Table 4 
and Figure 1). A lower value of both L3 SMI (Figure 2, 
p-value < 0.0001) and skeletal muscle CSA (Figure 3, 
p-value < 0.0001) has been showed to be significantly 
correlated with G3-4 toxicity also during (Time 1 in 
Figures 2 and 3) and after 4 cycles (Time 2 in Figures 2 
and 3) of chemotherapy. 
Finally, a multivariate analysis adjusted for basal 
BMI, BSA, L3 SMI and CSA revealed that L3 SMI was 
an independent predictor of severe toxicity (p = 0.0282). 
DISCUSSION
Sarcopenia is a common condition in cancer 
patients, due to altered protein catabolism [4]. Different 
instrumental techniques have been used to study body 
composition [6–10]. However, the evaluation of adipose 
tissue and LBM at the level of the L3 vertebra, performed 
by DXA and/or CT scan, appears to be the best choice 
[11, 13].
The European Working Group on sarcopenia 
recommends to evaluuate the presence of both low muscle 
mass and low muscle function (strength or performance) 
to determine sarcopenia [14]. However, in our study we 
analysed only the loss of muscle mass. In fact, being 
the study retrospective, it was not possible to collect 
informations about muscle function. 
Based on the hypothesis that body composition is 
relevant in drugs’ distribution and activity, we studied the 
association between sarcopenia and toxicities in breast 
cancer patients receiving adjuvant epirubicin-based 
treatment.
Several studies showed that the decrease of LBM 
is associated with higher chemotherapy toxicities, as well 
as a worse outcome in various cancer type [5, 15–40]. 
Moreover, a muscle wasting without adipose tissue and 
body weight reduction was observed during anticancer 
treatment with both chemotherapy and target therapy 
[25, 41]. Focusing on studies conducted on breast cancer, 
Prado and colleagues published a study performed on 55 
metastatic patients treated with capecitabine, evaluating 
muscle mass by CT scans at L3 vertebra level. About 25% 
of patients were identified as sarcopenic and 50% of them 
showed grade 2 or greater toxicities. Only 20% of non-
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sarcopenic patients had severe toxicities. They observed 
also a shorter time to progression (TTP) in sarcopenic 
patients [33]. Prado and colleagues conducted also a study 
on 24 breast cancer patients receiving adjuvant treatment, 
observing a higher LBM in patients without toxicity 
(p 0.002) and an association between epirubicin cleareance 
and LBM (p 0.041) [34]. Recently, Shachar and colleagues 
showed a significant association between sarcopenia and 
toxicities in metastatic breast cancer patients treated with 
taxanes (57% vs 18% of G3-4 toxicity in sarcopenic and 
non-sarcopenic group respectively, p 0.02) and in early 
breast cancer receiving anthracyclines and taxanes-based 
chemotherapy (G3-4 toxicity relative risk (RR) = 1.29 
for low skeletal muscle index (SMI), p 0.002; RR= 1.09 
for low skeletal muscle gauge (SMG), p 0.01) [35, 36]. 
Rier and colleagues observed an association between 
Table 1: Basal characteristic of the 21 enrolled patients
Number of patients %
Age (years)

































































FEC: 5-fluorouracil-Epirubicin-Cyclophosphamide; ET: Epirubicin-Docetaxel; EC: Epirubicin-Cyclophosphamide; AC: 
Adraimicin-Cyclophosphamide; Ptx: Paclitaxel; Txt: Docetaxel.
Table 2: BMI, BSA and lean body mass index for the 21 enrolled patients before and after treatment
Before treatment (T0) After treatment (T2)
Median Range Median Range
BMI (kg/cm2) 23.6 18.0–33.7 23.2 17.2–33.7
BSA (m2) 1.7 1.4–1.9 1.7 1.4–2.1
L3 SMI (cm2/m2) 39.2 31.6–52.9 39.2 31.6–52.9
skeletal muscle cross-sectional area (cm2) 103.3 82.6–143.9 104.5 83.2–135.5
Weigth (Kg) 63.5 46.0–82.0 60 44–95
Height (cm) 161 150–175 161 150–175
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low muscle attenuation (LMA) and shorter OS in 166 
metastatic breast cancers receiving first line chemotherapy 
[37]. Deluche and colleagues identified an association 
of L3 SMI with both DFS and OS in 119 breast cancer 
patients [38]. Finally, Villaseñor and colleagues observed 
that sarcopenia is associated with an increased risk of 
overall mortality in a cohort of 471 stage I–IIIA breast 
cancer patients [40].
Currently, the adjustment of anticancer drugs doses 
is based on physical parameters (weight, height and BSA), 
not considering changes in the relationship between 
fat and lean mass, typical of natural history of cancer 
patients [42]. Nevertheless, there are growing evidences 
that LBM can be a better parameter for the evaluation of 
chemotherapy doses. For instance, Gusella and colleagues 
demonstrated the wide correlation of the reduction in fat-
free mass with the decrease in distribution volume and 
clearance of 5-fluorouracil [43]. Muscle tissue, in fact, in 
addition to acts in drugs’ metabolism, is a large area of 
drugs’ distribution, being richly vascularized. So, when 
there is a muscle reduction, an increase in drugs’ plasma 
concentration occurs., This is usually associated with 
higher grade of toxicities [13].
A large part of our cohort is sarcopenic at diagnosis. 
This observation leads to consider that the main 
responsibles of muscle loss are tumor-related factors or 
pro-inflammatory cytokines, instead of chemotherapy 
related factors. Another hypotesis is that patients with 
diagnosis of breast cancer reduce their physical activity 
due to the decrease of the mood. 
In line with literature data we found that sarcopenic 
status was significantly associated to higher risk of 
Table 3: Toxicities reported during treatment for the 21 enrolled patients
G1-2 toxicity G3-4 toxicity
N % N %
Neutropenia 6 28.6 2 9.5
Anemia 11 52.4 0 0
Nausea 16 76.2 0 0
Vomit 7 33.3 1 4.8
Diarrhea 6 28.6 1 4.8
Constipation 3 14.3 0 0
Dysgeusia 9 42.9 0 0
Mucositis 5 23.8 1 4.8
Abdominal pain 2 9.5 1 4.8
Neurotoxicity 10 47.6 0 0
HFS 15 71.4 0 0
Cutaneous 4 19.0 0 0
Asthenia 17 81.0 0 0
Alopecia 21 100 0 0
Insomnia 5 23.8 0 0
Depression 2 9.5 0 0
Ocular 1 4.8 0 0
Fever 1 4.8 0 0
Table 4: Basal BMI, BSA, L3 index and skeletal muscle cross-sectional area according to absent/mild and severe CTC 
toxicity
Absent/mild toxicity (i.e. ≤G2) Sever toxicity (≥G3) p-value
BMI (kg/cm2) 26.4 (range: 18–33.7) 22.2 (range: 18.9–24.8) 0.12
BSA (m2) 1.7 (range: 1.4–1.9) 1.5 (range:1.4–1.7) 0.09
L3 SMI (cm2/m2) 40.5 (range: 33.4–52.0) 33.4 (range: 31.1–39.9) 0.028
skeletal muscle 
cross-sectional area (cm2)
109.0 (range: 83.3–143.9) 86.7 (range: 82.6–104.7) 0.017
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Figure 1: L3 Index, skeletal muscle cross-sectional area, BMI and BSA basal value in the 21 enrolled patients according 
to toxicity grade. 
Figure 2: L3 Index variation over time according to toxicity grade. The red line show the L3 SMI at T0, T1 and T2 for the group 
of patients with G0-2 toxicities, while the blue line represent the variation of L3 SMI for patients with severe toxicities. We can observe 
that patients with G3-4 toxicities have a lower L3 SMI.
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developing toxicities. Moreover, we observes that 
treatment induces a raise in sarcopenia frequency in about 
9.5% of the cases. This is probably due to the reduced 
food intake or to the reduced physical activity consequent 
to anticancer treatment. 
Even though the small sample size and the 
retrospectivity of the analysis, these findings suggest the 
importance to consider body composition in determining 
drugs’ doses. The prevention of LBM impairment could be 
useful to improve the quality of life of patients receiving 
chemotherapy.
During recent years, a growing interest in muscle 
mass maintenance in cancer patients has been observed. 
Most appetite stimulants or nutritional agents have 
been widely studied for prevention of cancer cachexia, 
leading to an increase in fat without an increase in lean 
body mass. Anabolic androgenic steroids showed more 
successful results in treating skeletal muscle wasting with 
an increased protein synthesis. The use of androgenic 
steroids is associated with several adverse events, such 
as hepatic toxicity, acne, increased sebum production, 
virilization and hirsutism in women. Moreover, there 
is a potential relation with prostate cancer and benign 
prostatic hyperplasia in men [44, 45]. Selective androgen 
receptor modulators (SARMs) are currently studied. 
The advantages of this class of drugs is that they can 
selectively induce anabolism without the accompanying 
androgenic side effects. Dobs and colleagues showed, in 
a recently completed phase II trial, a significant increase 
in lean body mass in patients treated with enobosarm than 
in patients treated with placebo [46]. Moreover, two phase 
III trials of enobosarm to treat sarcopenia in metastatic 
NSCLC undergoing first line therapy have been recently 
completed (POWER trials; https://clinicaltrials.gov 
NCT01355484 and NCT01355497), showing a gain in 
lean body mass in the experimental arm [47].
In conclusion, our results support literature data 
showing a relation between sarcopenia and toxicity in 
cancer patients. In fact, sarcopenia is associated to worse 
outcome, to higher risk of complication after surgical 
intervention, to higher mortality and to the risk of 
developing severe toxicities [5, 13]. In particular, adverse 
events are the major cause of dose reduction, delaying 
of administration and therapy discontinuation. Dose 
intensity loss avoidance has to be considered as a primary 
purpose of cancer treatment, above all in adjuvant setting. 
Furthermore, management of severe toxicities are a cause 
of health costs raise and quality of life impairment. 
Future clinical trials investigating dose assessment 
based on LBM status, along with studies on sarcopenia 
prevention, have the potential to personalize treatment and 
to improve outcome and quality of life during chemotherapy. 
Figure 3: Skeletal muscle cross-sectional area variation according to toxicity grade. The red line show the skeletal muscle 
CSA at T0, T1 and T2 for the group of patients with G0-2 toxicities, while the blue line represent the variation of skeletal muscle CSA for 




Stage I–III breast cancer patients who have 
received anthracycline-based adjuvant treatment at the 
Department of Medical Oncology, Sant’Andrea Hospital 
of Rome between February 2013 and April 2014 were 
retrospectively analysed. 
The eligibility criteria was: histological diagnosis of 
early breast cancer, adjuvant anthracycline-based adjuvant 
chemotherapy received for at least 4 cycles, CT scan 
available before (Time 0, T0), during (Time 1, T1) and 
after (Time 2, T2) adjuvant chemotherapy. 
BMI, BSA and toxicity according to the National 
Cancer Institute Common Toxicity Criteria (CTCAE) 
version 4.0 were assessed at each chemotherapy cycles. 
The primary end-point of this study is to assess the 
association between sarcopenia, expressed as L3 SMI and 
skeletal muscle CSA, and toxicity in early breast cancer 
patient receiving adjuvant anthracycline. The secondary 
end-points are to assess the prevalence of sarcopenia in 
early breast cancer patients and to explore the variation of 
lean body mass during chemotherapy.
All the patients signed an informed consent. The 
study was conducted in accordance with the Declaration 
of Helsinki and the institutional ethic committee approved 
the protocols.
Image analysis for sarcopenia 
Sarcopenia was evaluated by the analysis of 
available CT scan images performed before (T0), during 
(T1) and after (T2) adjuvant chemotherapy. A transverse 
section with a multiplanar reconstruction at L3 was 
used to study the following muscles: psoas, paraspinal, 
abdominal transverse rectum, internal and external 
obliques. Images were analysed by the software Slice 
Omatic V 5.0 (Montreal, Quebec, Canada Tomovision). 
The muscles areas were marked by the Hounsfield unit 
thresholds from −29 to + 150 and the total CSA were 
computed. The CSA obtained in this way are normalized 
according to patients’ height. Finally, the L3 SMI was 
calculated. According to previous published studies, 
sarcopenia was defined by a L3 SMI value ≤38.5 cm2/m2, 
because it is independent from BMI. Considering that 
obese or overweight patients could be sarcopenic, this 
cut-off is more useful to recognize sarcopenia, as showed 
by Prado and colleagues  [11].
Statistics
The data were given as mean ± SD or median (range) 
as appropriate. Boxplots of patient-related parameters 
over time were used to show variability among groups. 
Differences between groups were calculated by using a 
two-tailed t-test. Linear regression analyses were used to 
estimate correlations between toxicity-reported and patient-
related body composition data, carried-out before starting 
treatment, after the 2th and 4th cycle of chemotherapy. 
For the multivariate statistics, a stepwise forward multiple 
linear regression was performed. Differences were 
considered significant at p-value < 0.05. All statistics were 
calculated using R-Package (version 3.3.2). 
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